Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

A randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial.

2012; Lippincott Williams & Wilkins; Volume: 30; Issue: 4_suppl Linguagem: Inglês

10.1200/jco.2012.30.4_suppl.549

1527-7755

Paulo M. Hoff, Daniel Fernandes Saragiotto, Carlos H. Barrios, Auro del Giglio, Anelisa K. Coutinho, Aline C Andrade, Carolina Dutra, Nora Manoukian Forones, Mariangela Correa, Maria Socorro O Portella, Vanessa Q. Passos, Renata N. Chinen, Brigitte Van Eyll,

Colorectal Cancer Treatments and Studies

549 Background: Chemotherapy-induced diarrhea (CID) is a relatively common adverse event in the treatment of colorectal cancer patients. The LARCID trial evaluated the efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this population. Methods: Colorectal cancer patients starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil (5-FU), capecitabine and/or irinotecan were randomized to receive octreotide LAR, 30 mg intramuscularly every 4 weeks, (experimental arm) or the physician’s treatment of choice in case of diarrhea (control arm). Results: A total of 139 patients were randomized, most of which received 5-FU- and oxaliplatin-containing chemotherapy regimens. The rate of diarrhea was 76.1% in the experimental group (n=68) and 78.9% in the control group (n=71). Treatment with octreotide LAR did not prevent nor reduced the severity of CID. Treatment choices for diarrhea management included loperamide in the majority of cases. No benefit from octreotide LAR was identified in terms of need for diarrhea treatment, opioids, or intravenous hydration, nor in the rate of hospitalization, or quality-of-life. Conclusions: Octreotide LAR is not indicated for the prevention of CID.